More medical centers ordered medical isotope developer IsoRay's Proxcelan cesium-131 seeds for prostate cancer treatment to advance the Richland, WA, company's sales in fiscal 2008.
For the period (end-June 30), revenue increased 25% to $7.1 million, compared with $5.7 million in fiscal 2007. The net loss for fiscal 2008 decreased 11% to $8.5 million, compared with a net loss of $9.6 million in the previous fiscal year.
In the fourth quarter, sales rose to $1.7 million, up 7% from $1.6 million in the same quarter of fiscal 2007. The company's net loss declined to $1.4 million, compared with a net loss of $2.7 million in the previous year's fourth quarter.
Related Reading
IsoRay authorizes stock repurchase plan, June 3, 2008
IsoRay posts sales increase, net loss in Q3, May 14, 2008
IsoRay chief executive steps down, February 27, 2008
IsoRay takes stake in Russian manufacturer, January 23, 2008
IsoRay's cesium isotope used for eye cancer, December 13, 2007
Copyright © 2008 AuntMinnie.com
